NASDAQ · Biotechnology

Vor Biopharma Inc. (VOR) Stock

$20.36 +5.69% NASDAQ: VOR Healthcare

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer.

Valuation

MetricValue
Price$20.36
Market Cap$139.51M
P/E Ratio-0.03
P/B Ratio-0.06
P/S Ratio0.00
EPS (TTM)$-3.73
52-Week High$53.00
52-Week Low$6.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE87.31%
ROA-174.26%
ROCE-76.12%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.02
Current Ratio18.32

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-69.0M$-93.0M$-126.0M$-121.0M$-372.0M
Net Profit$-69.0M$-92.0M$-118.0M$-117.0M$-696.0M
EPS$-37.80$-46.60$-35.00$-34.00$-70.50
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$243.0M$299.0M$210.0M$143.0M$464.0M
Total Liabilities$26.0M$49.0M$59.0M$46.0M$628.0M
Cash$120.0M$58.0M$31.0M$82.0M$396.0M
Borrowings$18.0M$39.0M$36.0M$32.0M$3.0M

Latest News

Vor Bio Appoints David Zaccardelli to Board of Directors GlobeNewswire · Jul 7, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next Simply Wall St. · Jun 30, 2026 Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China GlobeNewswire · Jun 8, 2026 Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China GlobeNewswire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-69.0M$-85.0M$-100.0M$-100.0M$-143.0M
Investing Cash Flow$-96.0M$-103.0M$70.0M$97.0M$-50.0M
Financing Cash Flow$-2.0M$1.0M$-2.0M$-2.0M$-1.0M
Net Cash Flow$72.0M$-62.0M$-26.0M$51.0M$312.0M
Free Cash Flow$-73.0M$-94.0M$-101.0M$-100.0M$-144.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.08
FCF Yield-103.22%
Quick Ratio18.32
Interest Coverage0.00
Return 1Y-61.30%
Return 3Y-68.21%
Return 5Y-94.01%

Ownership

Insiders Held4.27%
Institutions Held75.28%
Institutions Float Held78.64%
Institutional HolderSharesReport Date
TCG Crossover Management, LLC5,673,0782026-03-31
RA Capital Management, L.P.5,404,9982026-03-31
FCPM III Services B.V.4,117,3542026-03-31
Venrock Adviser, LLC3,041,7192026-03-31
Frazier Life Sciences Management, L.P. 2,543,9392026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACTU $1.09 -5.22% -2.73 $26.08M 0.00%
ALEC $1.52 +0.33% -1.58 $168.20M 0.00%
ANIX $3.48 -1.14% -8.00 $118.40M 0.00%
APLTApplied Therapeutics, Inc. $0.10 +0.00% -0.24 $14.86M 0.00%
FATE $2.31 -0.43% -1.62 $269.25M 0.00%

About Vor Biopharma Inc.

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

Vor Biopharma Inc. is led by CEO Jean-Paul Kress, employs 159 people, headquartered in US, publicly traded since 2021.

Vor Biopharma Inc. (VOR) stock trades at $20.36 with a market capitalization of $139.51M. The stock is valued at a price-to-earnings (P/E) ratio of -0.03, price-to-book of -0.06, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $6.50 and $53.00, and currently trades 61.6% below its 52-week high.

On profitability, Vor Biopharma Inc. generates a return on equity (ROE) of 87.31% — well above the market average, a sign of a high-quality business, return on capital employed of -76.12%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.vorbio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides